Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $312,250.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the sale, the insider owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.23, for a total value of $153,450.00.
• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total value of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Stock Up 16.2%

Shares of NASDAQ XERS traded up $2.12 during mid-day trading on Friday, reaching $15.20. 7,890,466 shares of the company’s stock traded hands, compared to its average volume of 2,106,974. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business has a 50-day simple moving average of $9.49 and a 200 day simple moving average of $7.58. The stock has a market cap of $2.77 billion, a P/E ratio of -138.18 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $15.21.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Quarterly results beat estimates: Xeris reported Q3 2026 earnings of $0.06 per share versus consensus of $0.03, and revenue of $107.23 million versus expectations of $101.68 million. Xeris Q3 2026 results
• Positive Sentiment: More optimistic Recorlev outlook: CEO John Shannon reportedly expects Recorlev to approach $1 billion in annual sales three to four years earlier than previously anticipated, a potential growth catalyst. Reacorlev sales outlook
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed Outperform and lifted its target to $21 from $18; HC Wainwright raised its target to $18 from $10 and assigned a Buy rating. Read More. · Read More.
• Neutral Sentiment: Xeris updated its FY 2030 earnings guidance, but the provided report does not include the revised figures. Several insiders also reported sales made under pre-arranged trading plans; these transactions may be less informative than discretionary sales. Read More.
• Negative Sentiment: Piper Sandler maintained a Neutral rating but raised its target to $12 from $8, still below the approximately $14.92 share price cited in the report, signaling valuation concerns despite the target increase. Read More.

Wall Street Analyst Weigh In

Several research firms recently weighed in on XERS. Barclays upped their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Oppenheimer restated an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Leerink Partners increased their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. HC Wainwright raised their price target on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.20.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors have recently bought and sold shares of the stock. Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Xeris Biopharma during the 3rd quarter worth approximately $1,275,000. StoneX Group Inc. purchased a new position in shares of Xeris Biopharma during the third quarter valued at approximately $142,000. Pictet Asset Management Holding SA raised its holdings in shares of Xeris Biopharma by 13.7% in the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company’s stock worth $326,000 after buying an additional 4,108 shares during the period. AlphaCentric Advisors LLC boosted its holdings in Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after acquiring an additional 1,940 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in Xeris Biopharma by 3.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 213,337 shares of the company’s stock worth $2,040,000 after acquiring an additional 7,482 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.